FDA AI Strategy Faces Uncertainty After High-Level Turnover
High-level turnover at the FDA has introduced uncertainty about how quickly the agency's agency-wide AI strategy will move forward.
Digital Health / MedTech / BioTechDigital Health / MedTech / BioTech
Fauci to Testify Before Senate Panel Again
Anthony Fauci, the nation's former top infectious disease expert, is scheduled to testify before Congress again tomorrow at the Senate homeland security committee.
Digital Health / MedTech / BioTechSenate Delays Vote on CDC Nominee
The Senate health panel delayed until next week a vote on Erica Schwartz to run the Centers for Disease Control and Prevention, after postponing a separate vote on Sean Kaufman for a key public health preparedness role.
Digital Health / MedTech / BioTechMedicaid Funding Deferrals Spark Concerns Over Provider Taxes
The Centers for Medicare and Medicaid Services (CMS) has proposed a new rule to codify limits on Medicaid provider taxes, aimed at preventing states from guaranteeing providers will be refunded for their taxes.
Digital Health / MedTech / BioTechMedicare Advantage Insurers Face Scrutiny Over AI and Care Denials
Sens. Richard Blumenthal (D-Conn.) and Josh Hawley (R-Mo.) are calling on the nation's largest Medicare Advantage insurers to provide internal records and detailed information on their use of artificial intelligence to block rehabilitative care.
Digital Health / MedTech / BioTechMedicare Proposes Dramatic Cuts to 340B Drug Discounts for Hospitals
Medicare is proposing a 33.4% cut in payments to hospitals for drugs acquired through the 340B drug discount program, which would dramatically reduce the discounts currently being offered.
Digital Health / MedTech / BioTechElevance Sues Government Over Medicare Advantage Star Ratings Recalculation
Elevance Health has sued the U.S. government, alleging that federal efforts to recalculate its Medicare Advantage quality ratings didn't align with a recent court ruling, costing the health insurer $115 million.
Digital Health / MedTech / BioTechEli Lilly's Obesity Drug Sparks Controversy Over Access
Democratic lawmakers are pressing the Trump administration on who received special access to Eli Lilly's experimental obesity drug, retatrutide, via the FDA's compassionate use program.
Digital Health / MedTech / BioTech